An excipient from Trigonella foenum-graceum seeds and a process for preparation thereof is disclosed. The excipient obtained from Trigonella foenum-graceum seeds, comprising insoluble and soluble dietary fibers can be used in various phar maceutical or cosmetic compositions and food, nutritional or dietary prepara...

The present invention discloses compositions comprising fenugreek hydrocolloids comprising soluble and insoluble dietary fibers. The present invention further relates to the use of these compositions comprising fenugreek hydrocolloids as healthcare, personal care, food, household care and industrial products. ...

The present invention relates to a novel dispersible tablet composition, which comprises of a pharmacologically active ingredient and at least one excipient, which reduces the sedimentation rate of active ingredient. This invention further relates to a process for the preparation of a dispersible tablet of a pharmac...

The present invention relates to modified release compositions comprising multitude of modified release beads. The modified release beads comprise a matrix of at least one active ingredient at least one ion exchange resin at least one non polymeric multifunctional excipient; substantially coated with at least one ou...

The present invention relates to gastroretentive dosage forms of gamma aminobutyric acid ("GABA") analogs, and to processes for preparation of the same. The present invention provides gastroretentive dosage forms comprising GABA analog, at least one swelling agent and at least one non-swelling release retardant. ...

The present invention relates to oral care compositions and to method of maintaining oral health. The oral care composition of the present invention comprises at least one carbon dioxide source at least one acid source at least one abrasive and one or more pharmaceutically acceptable excipients. ...

The present invention relates to dietary fiber compositions comprising fenugreek dietary fibers. The present invention also relates to use of these compositions as dietary supplements, functional foods or pharmaceutical preparations for promoting satiety and weight loss. lowering cholesterol, controlling blood gluco...

The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers. ...

The present invention relates to controlled release pharmaceutical formulations of direct thrombin inhibitors and processes for preparing such compositions. Particularly the present invention relates to oral controlled release pharmaceutical compositions comprising dabigatran etexilate or pharmaceutically acceptable...

The present invention provides a controlled release formulation comprising an therapeutically effective amount of vitamin C, at least glyceryl ester, and at least one cellulose ether. The said dosage form provides substantially complete and controlled release of the vitamin C with reduced initial burst release. ...

The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.

A novel solvent free process of obtaining an insoluble fiber rich fraction from Trigonella Foenum-graecum seeds is disclosed. The multifunctional fiber rich fraction (FRF) and highly purified FRF are useful as excipients for pharmaceutical dosage forms for various routes of administration. These excipients can be us...

The present invention relates to the method of increasing the bioavailability of Angiotensin II Receptor Blockers (ARBs) by preparing a composition of an ARB with at least one solubility enhancing agent. In particular, the present invention relates to solubility enhancing agents that not only act as solubility enhan...

A directly compressible composite for an orally disintegrating tablet comprising at least one water-soluble excipient and calcium silicate prepared by co-processing.

The present invention relates to a novel dispersible tablet composition, which comprises of a pharmacologically active ingredient and at least one excipient, which reduces the sedimentation rate of active ingredient. This invention further relates to a process for the preparation of a dispersible tablet of a pharmac...

The present invention provides a controlled release formulation comprising an therapeutically effective amount of pharmacologically active substance having high water solubility, at least one non-polymeric release retardant, and at least one pH independent non-swelling release retarding polymer. The said dosage form...

The present invention relates to the methods of increasing the bioavailability of Angiotensin II Recptor Blockers (ARBs) by treating it with at least one absorption augmenting agent. In particular, the present invention relates to use of absorption augmenting agents which results in significant increase in the bioav...

Highly compressible controlled delivery compositions of metformin or salts thereof and the process of making the same are disclosed. Metformin is granulated with a binder and further dispersed in a rate-controlling matrix that results in increased hardness and decreased friability thereby effectively solving compres...

A novel solid oral dosage form comprising a therapeutically effective amount of hydrophobic pharmacological active ingredient and at least one particle separating agent preferably selected from a class of wetting agents, prepared without or with minimum amount of a disintegrating agent. The hydrophobic pharmacologic...

Sustained release compositions comprising plurality of sustained release beads are disclosed. Particularly the sustained release beads comprise coated drug resin complexes comprising drug resin complexes of at least one active agent and at least one ion exchange resin; coated with at least one release modifier. ...

The present invention relates to modified release compositions comprising plurality of modified release units. Particularly the modified release units comprise at least one anti Alzheimer s agent at least one ion exchange resin and at least one release modifier.

The present invention provides particulate delivery systems comprising plurality of particles comprising fenugreek gum and at least one pharmaceutically acceptable excipient. The particulate delivery systems of the present invention are used for the delivery of therapeutic immunologic or diagnostic agents and the li...

The present invention relates to oral modified release compositions comprising plurality of modified release matrix particles and at least one pharmaceutically acceptable excipient; wherein the modified release matrix particles comprise at least one active agent at least one release controlling agent and at least on...

The present invention relates to multiple unit extended release pharmaceutical compositions comprising plurality of modified release units wherein each unit comprises of an active agent core comprising at least one pharmaceutically active agent and at least one pharmaceutically acceptable excipient substantially coa...

The present invention is directed to a pharmaceutical formulation of esketamine for nasal administration. The present invention further relates to pharmaceutical formulations of esketamine delivered through unit-dose nasal spray devices. The invention also relates to a process for the preparation of such a compositi...

The present invention relates to modified release formulations of levodopa. Particularly the invention relates to modified release formulation of levodopa that offers reduced dosing frequency.